Episode Details
Back to Episodes
What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors
Season 23
Episode 23
Published 2 years, 3 months ago
Description
Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma.